CN115261114A - 一种具有降血糖和降血胆固醇功效的播娘蒿籽油 - Google Patents
一种具有降血糖和降血胆固醇功效的播娘蒿籽油 Download PDFInfo
- Publication number
- CN115261114A CN115261114A CN202210803200.5A CN202210803200A CN115261114A CN 115261114 A CN115261114 A CN 115261114A CN 202210803200 A CN202210803200 A CN 202210803200A CN 115261114 A CN115261114 A CN 115261114A
- Authority
- CN
- China
- Prior art keywords
- artemisia
- seed oil
- preparation
- persicae
- cholesterol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000015112 vegetable and seed oil Nutrition 0.000 title claims abstract description 83
- 210000004369 blood Anatomy 0.000 title claims abstract description 36
- 239000008280 blood Substances 0.000 title claims abstract description 36
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract description 62
- 230000000694 effects Effects 0.000 title abstract description 19
- 244000264242 Descurainia sophia Species 0.000 title abstract 5
- 235000017680 Descurainia sophia Nutrition 0.000 title abstract 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 37
- 239000003208 petroleum Substances 0.000 claims abstract description 20
- 239000000843 powder Substances 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 13
- 239000000706 filtrate Substances 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 230000036541 health Effects 0.000 claims abstract description 9
- 238000001914 filtration Methods 0.000 claims abstract description 8
- 238000001704 evaporation Methods 0.000 claims abstract description 7
- 238000000227 grinding Methods 0.000 claims abstract 3
- 235000003826 Artemisia Nutrition 0.000 claims description 57
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 57
- 244000030166 artemisia Species 0.000 claims description 57
- 235000009052 artemisia Nutrition 0.000 claims description 57
- 238000002360 preparation method Methods 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 21
- 235000004043 Artemisia persica Nutrition 0.000 claims description 15
- 241001201020 Artemisia persica Species 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 13
- 235000005714 Artemisia indica Nutrition 0.000 claims description 10
- 244000067509 Artemisia indica Species 0.000 claims description 10
- 235000013305 food Nutrition 0.000 claims description 9
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims description 8
- 240000008620 Fagopyrum esculentum Species 0.000 claims description 8
- 235000019198 oils Nutrition 0.000 claims description 7
- 238000009835 boiling Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- 230000008020 evaporation Effects 0.000 claims description 4
- 239000003472 antidiabetic agent Substances 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 9
- 150000004670 unsaturated fatty acids Chemical class 0.000 abstract description 8
- 235000021122 unsaturated fatty acids Nutrition 0.000 abstract description 8
- 150000008442 polyphenolic compounds Chemical class 0.000 abstract description 4
- 235000013824 polyphenols Nutrition 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 238000011161 development Methods 0.000 abstract description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 abstract 3
- 241001465382 Physalis alkekengi Species 0.000 abstract 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 abstract 1
- 229930003944 flavone Natural products 0.000 abstract 1
- 150000002212 flavone derivatives Chemical class 0.000 abstract 1
- 235000011949 flavones Nutrition 0.000 abstract 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 abstract 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 22
- 235000012000 cholesterol Nutrition 0.000 description 15
- 241000699673 Mesocricetus auratus Species 0.000 description 14
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 14
- 229920001268 Cholestyramine Polymers 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 10
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 10
- 235000001405 Artemisia annua Nutrition 0.000 description 10
- 240000000011 Artemisia annua Species 0.000 description 10
- 239000002775 capsule Substances 0.000 description 10
- 239000013641 positive control Substances 0.000 description 9
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 7
- 229940076810 beta sitosterol Drugs 0.000 description 7
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 7
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 7
- 229950005143 sitosterol Drugs 0.000 description 7
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 7
- 229940032091 stigmasterol Drugs 0.000 description 7
- 235000016831 stigmasterol Nutrition 0.000 description 7
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 208000035150 Hypercholesterolemia Diseases 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 201000001421 hyperglycemia Diseases 0.000 description 5
- 229940068065 phytosterols Drugs 0.000 description 5
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 4
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 4
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 4
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 4
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 4
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 4
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 4
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 4
- 235000000431 campesterol Nutrition 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 230000000260 hypercholesteremic effect Effects 0.000 description 4
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 4
- 229940058690 lanosterol Drugs 0.000 description 4
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 3
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000008157 edible vegetable oil Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000008821 health effect Effects 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- HVGRZDASOHMCSK-UHFFFAOYSA-N (Z,Z)-13,16-docosadienoic acid Natural products CCCCCC=CCC=CCCCCCCCCCCCC(O)=O HVGRZDASOHMCSK-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000032170 Descurainia Species 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000025584 Pericardial disease Diseases 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 210000004618 arterial endothelial cell Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- CVCXSNONTRFSEH-UHFFFAOYSA-N docosa-2,4-dienoic acid Chemical compound CCCCCCCCCCCCCCCCCC=CC=CC(O)=O CVCXSNONTRFSEH-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229960000815 ezetimibe Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- -1 lard Substances 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B1/00—Production of fats or fatty oils from raw materials
- C11B1/02—Pretreatment
- C11B1/04—Pretreatment of vegetable raw material
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B1/00—Production of fats or fatty oils from raw materials
- C11B1/10—Production of fats or fatty oils from raw materials by extracting
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B3/00—Refining fats or fatty oils
- C11B3/001—Refining fats or fatty oils by a combination of two or more of the means hereafter
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B3/00—Refining fats or fatty oils
- C11B3/008—Refining fats or fatty oils by filtration, e.g. including ultra filtration, dialysis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Diabetes (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种具有降血糖和降血胆固醇功效的播娘蒿籽油,属于天然药物领域。通过将娘蒿籽研磨成粉,再将粉末与石油醚按一定比例混合过滤,把滤渣与石油醚再次混合过滤,合并两次滤液用旋转蒸发仪上蒸发浓缩得到播娘蒿籽油,并回收石油醚。本方案制得的播娘蒿籽油备含有丰富的植物甾醇、黄酮、多酚及不饱脂肪酸,适合不同人群的健康需求,具有降血糖和血胆固醇的作用,有助于治疗心血管疾病药物的开发。
Description
技术领域
本发明涉及天然药物领域,特别涉及一种具有降血糖和降血胆固醇功效的播娘蒿籽油。
背景技术
随着人民生活水平的提高和人口的老龄化,心血管疾病发病率呈上升趋势,成为世界范围内威胁人类健康的主要疾病之一,心血管疾病的死亡率要高于肿瘤及其他疾病,心血管疾病是心脏血管疾病的统称,主要由先天性疾病和后天致病原因引起的心脏和血管的疾病,有冠心病、高血压病、心包性疾病、血管性疾病等。高胆固醇血症是导致心血管疾病的重要危险因素之一,治疗高胆固醇血症的药物主要有他汀类、消胆胺和依泽替米贝,但长期服用会导致严重的副作用。此外,因为人们不良的生活习惯以及精神上的压力,使得高血糖患者越来越多,在长期高血糖的作用下,动脉内皮细胞容易受损,血管壁的通透性也会变差,脂质容易沉积在血管内皮,进而导致血管狭窄,容易引起冠心病等心血管疾病。目前还没有完全根治高血糖的药物,只能通过口服降糖药和胰岛素来降低血糖,或者通过日常饮食进行调理。近些年,有研究者发现许多存在于食物中的油脂,因富含大量的活性成分(如多不饱脂肪酸、植物甾醇、黄酮等)而对胆固醇代谢和高血糖具有一定的改善效果,功能性油脂因可以发挥与药物类似的功效以及无副作用的特点,开始逐渐被重视并成为治疗高胆固醇血症药物的潜在替代品。
播娘蒿(Descurainia sophia(L.)Webb.ex Prantl)属一年生草本植物,且分布于中国各地,产量较多,播娘蒿种子含油40%,可食用也可以药用,具有利尿消肿、祛痰定喘的效用。目前播娘蒿的研究主要侧重于提取工艺以及活性物质的研究,对于播娘蒿食用后的保健功效研究较少,如果能通过研究播娘蒿的保健功效从而开发一种具有降低血糖和血胆固醇的功能性油脂,可为阐述播娘蒿的效果提供实验依据,还有助于天然油脂资源以及治疗心血管疾病药物的开发。
发明内容
本发明的目的在于提供一种具有降低血糖和降血胆固醇功效的播娘蒿籽油,以解决现有降血糖和降胆固醇药物有严重的副作用以及播娘蒿保健功效研究较少的问题。
为了实现上述目的,本发明的技术方案如下:
一种播娘蒿籽油的制备方法,所述制备方法包括:
步骤1:将播娘蒿籽研磨成粉;
步骤2:将步骤1中的播娘蒿籽粉与石油醚按一定比例充分混匀浸泡,过滤混合物后收集第一次滤液;
步骤3:用步骤2中浸泡后的残余物与石油醚按一定比例再次浸泡,过滤混合物后取第二次滤液;
步骤4:合并步骤2和步骤3的提取液蒸发浓缩得到播娘蒿籽油。
在其中一个实施例中,步骤1中,所述研磨成粉为研磨成35-55目的粉末。
在其中一个实施例中,步骤2中,所述石油醚的沸程为30-60℃。
在其中一个实施例中,步骤2中,所述播娘蒿籽粉与石油醚的料液比为1:(10-20)。
在其中一个实施例中,步骤3中,浸泡后的残余物与石油醚的料液比为1:(10-20)。
在其中一个实施例中,步骤4中,所述蒸发浓缩的温度为55-65℃,转速为135-165r/min。
在其中一个实施例中,所述蒸发浓缩的温度为50℃,转速为150r/min。
在其中一个实施例中,所述的一种播娘蒿籽油的制备方法所制备的播娘蒿籽油在制备降血糖药品、食品或保健品中的应用。
在其中一个实施例中,所述的一种播娘蒿籽油的制备方法所制备的播娘蒿籽油在制备降血胆固醇药品、食品或保健品中的应用
具体地,将本发明得到的播娘蒿籽油进行精制,经脱胶,脱酸,脱色和脱臭处理后去除各种杂质,再加入药学上可接受的辅料得到药用原料,将该药用原料加工成口服液、片剂、颗粒剂、丸剂或充入胶囊,制得能降低高血糖或降血胆固醇的药物。或者将得到的播娘蒿籽油经过脱脂、脱胶、脱水、脱色、脱臭、脱酸后加工成符合食用油质量标准和卫生标准的食用油,可直接用于食用,或与鱼肝油、蛋黄油、奶油等动物油按2:1的体积比结合食用。再或者制成含有播娘蒿籽油的保健品,具体操作包括:1)将播娘蒿籽油、菜籽油、大豆油、维生素B、维生素C按照60:10:10:0.5:0.5的质量比混合均匀制成囊心液;2)将食品级明胶、甘油、水、柠檬酸、山梨醇按照为40:20:30:2:8的质量比制成胶囊壳,包括:先将食品级明胶和配方量50%的水混合后静置至明胶充分水膨胀,再将甘油、水、柠檬酸、山梨醇加入溶胶罐中,加入剩余的水加热至60℃搅拌溶解,然后将明胶和水的混合物加入溶胶罐中搅拌均匀,最后经超声脱气处理制得胶囊壳;3)将制得的囊心液和胶囊壳导入胶囊机中制成胶丸,冷风固化成型后用可食用乙醇除去胶丸表面油层,经40℃热风干燥制得具有降血糖或降血胆固醇功效的胶囊。必要时还可以制成其他剂型。
本发明的有益效果如下:
本发明通过粉碎、浸泡过滤、二次浸泡过滤、蒸发浓缩提供了一种播娘蒿籽油,所述播娘蒿籽油含有麦角甾醇、菜油甾醇、豆甾醇、β-谷甾醇、柱头固醇、羊毛甾醇,其中β-谷甾醇含量最高,还含有丰富的不饱和脂肪酸、黄酮以及多酚,适合不同人群的健康需求,具有降血糖和血胆固醇的作用,有助于治疗心血管疾病药物的开发。
附图说明
为了更清楚地说明本发明的技术方案,下面将对实施方式中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施方式,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1是高胆固醇血症金黄地鼠分别在第0、3周的血糖水平柱状图,图中:NCD为无胆固醇对照组;PCD为消胆胺阳性对照组;HCD为高胆固醇对照组;LPD为低剂量播娘蒿籽油实验组;HPD为高剂量播娘蒿籽油实验组;a、b代表均值在P<0.05时差异显著。
图2是高胆固醇血症金黄地鼠分别在第0、3周的总胆固醇(TC)柱状图,图中:NCD为无胆固醇对照组;PCD为消胆胺阳性对照组;HCD为高胆固醇对照组;LPD为低剂量播娘蒿籽油实验组;HPD为高剂量播娘蒿籽油实验组;a、b代表均值在P<0.05时差异显著。
图3是高胆固醇血症金黄地鼠分别在第0、3周的非高密度脂蛋白胆固醇(Non-HDL-C)柱状图,图中:NCD为无胆固醇对照组;PCD为消胆胺阳性对照组;HCD为高胆固醇对照组;LPD为低剂量播娘蒿籽油实验组;HPD为高剂量播娘蒿籽油实验组;a、b代表均值在P<0.05时差异显著。
图4是高胆固醇血症金黄地鼠分别在第0、3周的Non-HDL-C/HDL-C比值柱状图,图中:NCD为无胆固醇对照组;PCD为消胆胺阳性对照组;HCD为高胆固醇对照组;LPD为低剂量播娘蒿籽油实验组;HPD为高剂量播娘蒿籽油实验组;a、b代表均值在P<0.05时差异显著。
图5是高胆固醇血症金黄地鼠分别在第0、3周的HDL-C/TC比值柱状图,图中:NCD为无胆固醇对照组;PCD为消胆胺阳性对照组;HCD为高胆固醇对照组;LPD为低剂量播娘蒿籽油实验组;HPD为高剂量播娘蒿籽油实验组;a、b代表均值在P<0.05时差异显著。
具体实施方式
下面对本发明实施方式中的技术方案进行清楚、完整地描述。在此需要说明的是,对于这些实施方式的说明用于帮助理解本发明,但并不构成对本发明的限定。此外,下面所描述的本发明各个实施方式中所涉及的技术特征只要彼此之间未构成冲突就可以相互组合。下述实施例中的实验方法,如无特殊说明,均为常规说法。
实施例1:播娘蒿籽油的制备
具体制备包括下列步骤:
先用研磨机将播娘蒿籽(来源于中国河南省)研磨成粉,过40目筛得播娘蒿籽粉;然后将播娘蒿籽粉与石油醚(沸程40℃)按1:15的料液比(g/mL)充分混匀浸泡24小时,过滤混合物,取第一次滤液;将浸泡后的残余物与石油醚按1:15的料液比(g/mL)再次浸泡24小时,过滤混合物,取第二次滤液;最后合并两次提取液,于旋转蒸发仪上蒸发,设置蒸发温度为50℃,蒸发转速为150r/min,浓缩得到播娘蒿籽油,并回收石油醚。
实施例2:一种播娘蒿籽油
制备方法同实施例1,不同之处在于,播娘蒿籽粉与石油醚(沸程30℃)按1:10料液比充分混匀浸泡24小时,过滤混合物,取第一次滤液。将浸泡后的残余物与石油醚按1:10料液比再次浸泡24小时,过滤混合物,取第二次滤液。
实施例3:一种播娘蒿籽油
制备方法同实施例1,不同之处在于,将播娘蒿籽粉与石油醚(沸程60℃)按1:20料液比充分混匀浸泡24小时,过滤混合物,取第一次滤液。将浸泡后的残余物与石油醚按1:20料液比再次浸泡24小时,过滤混合物,取第二次滤液。
实施例4:一种播娘蒿籽油
制备方法同实施例1,不同之处在于,将播娘蒿籽粉与石油醚(沸程40℃)按1:20料液比充分混匀浸泡24小时,过滤混合物,取第一次滤液。将浸泡后的残余物与石油醚按1:10料液比再次浸泡24小时,过滤混合物,取第二次滤液。
实验例1:播娘蒿籽油的功能性成分分析
实施例1-4均可以得到播娘蒿籽油,但是结合制备成本以及提取效率,加上制得的播娘蒿籽油成分相差不大,因此采用实施例1制得的播娘蒿籽油用于后续分析实验。
1、通过气相色谱仪(7890B,安捷伦)对实施例1制得的播娘蒿籽油进行分析。
表1播娘蒿籽油中植物甾醇的组成及含量表
保留时间(min) | 植物甾醇种类 | 平均含量(mg/100g) | 相对百分含量(%) |
11.953±0.000 | 麦角甾醇 | 3.19±0.12 | 0.78±0.16 |
12.447±0.004 | 菜油甾醇 | 89.06±41.52 | 20.96±1.11 |
13.108±0.007 | 豆甾醇 | 13.01±7.05 | 3.97±3.76 |
14.556±0.001 | β-谷甾醇 | 270.56±35.57 | 62.73±7.09 |
14.981±0.003 | 柱头固醇 | 37.95±11.42 | 10.25±5.76 |
16.310±0.000 | 羊毛甾醇 | 2.04±0.05 | 0.50±0.07 |
其它 | 3.28±1.69 | 0.81±0.40 |
表2播娘蒿籽油中的脂肪酸组成及含量表
实验结果:
由表1可知,播娘蒿籽油主要有6种植物甾醇,包括麦角甾醇、菜油甾醇、豆甾醇、β-谷甾醇、柱头固醇、羊毛甾醇。其中菜油甾醇含量为89.06mg/100g,占比20.96%;β-谷甾醇含量为270.56mg/100g,占比62.73%;柱头固醇含量为37.95mg/100g,占比10.25%,而麦角甾醇、豆甾醇、羊毛甾醇的占比含量较少。因此,播娘蒿籽油中β-谷甾醇含量最高。
由表2可知,播娘蒿籽油含有饱和脂肪酸和不饱和脂肪酸,且不饱和脂肪酸相对含量高达75.14%,不饱和脂肪酸中多不饱和脂肪酸占总脂肪酸含量的42.44%,单不饱和脂肪酸占比32.70%。不饱和脂肪酸中油酸和α-亚麻酸的含量最多,其次含量较多的是花生烯酸、二十二碳二烯酸、亚油酸等。
2、采用分光光度法对实施例1制得的播娘蒿籽油进行分析,经广州分析测试中心测得总黄酮含量为7.88mg/100g,总多酚含量为31.7mg/kg。
实验例2:分析播娘蒿籽油对高胆固醇血症金黄地鼠血糖和血胆固醇的影响
1、实验设计
将40只来源于北京维通利华的雄性金黄地鼠(6-8周龄,100-120g)随机分为5组(n=8),分别饲喂对应的日粮,置于动物房中,光/暗周期为12/12小时,温度保持在23℃。实验周期为3周,这期间自由饮水和摄食,于第0、3周禁食过夜后,在异氟醚轻度吸入麻醉下从眼眶后窦采血,测定血清中胆固醇和血糖的含量。
2、制备鼠粮
无胆固醇日粮组(NCD)是由玉米淀粉、酪蛋白、蔗糖、猪油、矿物质、维生素、明胶、DL-蛋氨酸混合而成;高胆固醇日粮组(HCD)在NCD的基础上添加0.15%胆固醇;阳性对照组(PCD)在HCD的基础上再添加0.5%消胆胺;低剂量播娘蒿籽油组(LPD)在HCD基础上使用播娘蒿籽油替代50%猪油;高剂量播娘蒿籽油(HPD)在HCD基础上使用播娘蒿籽油替代100%猪油。鼠粮的配方如下表3所示:
表3配粮表
3、测试播娘蒿籽油对高胆固醇血症金黄地鼠生化指标变化的影响
使用UV2365紫外可见分光光度计【尤尼科(上海)有限公司】来分别测定无胆固醇对照组(NCD)、消胆胺阳性对照组(PCD)、高胆固醇对照组(HCD)、低剂量播娘蒿籽油实验组(LPD)或高剂量播娘蒿籽油实验组(HPD)的血糖含量、总胆固醇(TC)、非高密度脂蛋白胆固醇(Non-HDL-C)、非高密度脂蛋白胆固醇/高密度脂蛋白胆固醇比值(Non-HDL-C/HDL-C比值)以及高密度脂蛋白胆固醇比值/总胆固醇比值(HDL-C/TC比值)。
实验结果:
如图1所示,第0周时,五组金黄地鼠的血糖水平相近,无显著性差异(P>0.05)。饲喂3周后,与高胆固醇对照组(HCD)相比,消胆胺阳性对照组(PCD)提高血糖水平5.83%;无胆固醇对照组(NCD)、低剂量播娘蒿籽油实验组(LPD)、高剂量播娘蒿籽油实验组(HPD)能显著降低血糖水平6.46%、9.17%、14.58%(P<0.05),具体地,低剂量播娘蒿籽油实验组(LPD)血糖为4.36mmol/L;高剂量播娘蒿籽油实验组(HPD)血糖为4.10mmol/L;血糖水平低于无胆固醇对照组(NCD)血糖为4.49mmol/L。因此,食用播娘蒿籽油能有效维持正常血糖水平,而服用消胆胺,则有升高血糖的副作用。
由图2可知,第0周时,五组金黄地鼠的血清总胆固醇(TC)水平相近,无显著性差异(P>0.05)。饲喂3周后,高胆固醇对照组(HCD)较无胆固醇对照组(NCD)显著提高血清总胆固醇(TC)水平35.07%(P<0.05);与高胆固醇对照组(HCD)相比,低剂量播娘蒿籽油实验组(LPD)、高剂量播娘蒿籽油实验组(HPD)分别能降低血清总胆固醇(TC)水平6.87%、15.07%(P<0.05),证明播娘蒿籽油能有效降低胆固醇血症金黄地鼠血清总胆固醇的水平,并呈剂量依赖性,高剂量效果更好。
由图3可知,第0周时,五组金黄地鼠的血清非高密度脂蛋白胆固醇(Non-HDL-C)水平相近,无显著性差异(P<0.05)。饲喂3周后,高胆固醇对照组(HCD)较无胆固醇对照组(NCD)显著提高血清非高密度脂蛋白胆固醇(Non-HDL-C)水平77.54%(P<0.05);与HCD组相比,低剂量播娘蒿籽油实验组(LPD)、高剂量播娘蒿籽油实验组(HPD)能显著降低血清非高密度脂蛋白胆固醇(Non-HDL-C)水平12.23%、32.18%(P<0.05)。
如图4所示,第0周时,五组金黄地鼠血清Non-HDL-C/HDL-C比值水平相近,无显著性差异(P>0.05)。饲喂3周后,高胆固醇对照组(HCD)较无胆固醇对照组(NCD)显著提高血清Non-HDL-C/HDL-C比值水平84.28%(P<0.05);与高胆固醇对照组(HCD)相比,低剂量播娘蒿籽油实验组(LPD)、高剂量播娘蒿籽油实验组(HPD)显著降低血清Non-HDL-C/HDL-C比值水平14.7%、37.21%(P<0.05)。
HDL-C/TC的比值动脉粥样硬化呈负相关。由图5可知,第0周时,五组金黄地鼠的血清HDL-C/TC比值水平相近,无显著性差异(P>0.05)。饲喂3周后,高胆固醇对照组(HCD)较无胆固醇对照组(NCD)显著降低了血清HDL-C/TC比值水平25%(P<0.05);与高胆固醇对照组(HCD)相比,低剂量播娘蒿籽油实验组(LPD)、高剂量播娘蒿籽油实验组(HPD)能显著提高血清HDL-C/TC比值水平8.88%、24.44%(P<0.05)。而且高剂量播娘蒿籽油实验组(HPD)的HDL-C/TC的比值(0.56)与消胆胺阳性对照组(PCD)HDL-C/TC的比值(0.60)相近,证明高剂量播娘蒿籽油与消胆胺的效果相仿,在一定程度上能预防心血管的病变。
综上所述,本发明制得的播娘蒿籽油富含多种对胆固醇代谢具有改善效果的功能成分,包括植物甾醇、黄酮、多酚、不饱和脂肪酸等,其中β-谷甾醇在植物甾醇中占比最高且能明显降低血清胆固醇的功效,同时播娘蒿籽油中的不饱和脂肪酸相对含量高达75.14%,因此,播娘蒿籽油具有降血糖和胆固醇的功效。另外,相比消胆胺这类常用降低胆固醇的药物,播娘蒿籽油的降血糖效果要更好,并且具有剂量依赖性,高剂量比低剂量的效果好,加上播娘蒿籽油无副作用的特点,使得播娘蒿籽油适合不同人群的健康需求,具有广泛的市场前景和应用价值。
以上所述是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也视为本发明的保护范围。
Claims (9)
1.一种播娘蒿籽油的制备方法,其特征在于,所述制备方法包括:
步骤1:将播娘蒿籽研磨成粉;
步骤2:将步骤1中的播娘蒿籽粉与石油醚按一定比例充分混匀浸泡,过滤混合物后收集第一次滤液;
步骤3:用步骤2中浸泡后的残余物与石油醚按一定比例再次浸泡,过滤混合物后取第二次滤液;
步骤4:合并步骤2和步骤3的提取液蒸发浓缩得到播娘蒿籽油。
2.根据权利要求1所述的一种播娘蒿籽油的制备方法,其特征在于,步骤1中,所述研磨成粉为研磨成35-55目的粉末。
3.根据权利要求1所述的一种播娘蒿籽油的制备方法,其特征在于,步骤2中,所述石油醚的沸程为30-60℃。
4.根据权利要求1所述的一种播娘蒿籽油的制备方法,其特征在于,步骤2中,所述播娘蒿籽粉与石油醚的料液比为1g:(10-20)mL。
5.根据权利要求1所述的一种播娘蒿籽油的制备方法,其特征在于,步骤3中,浸泡后的残余物与石油醚的料液比为1g:(10-20)mL。
6.根据权利要求1所述的一种播娘蒿籽油的制备方法,其特征在于,步骤4中,所述蒸发浓缩的温度为55-65℃,转速为135-165r/min。
7.根据权利要求6所述的一种播娘蒿籽油的制备方法,其特征在于,所述蒸发浓缩的温度为50℃,转速为150r/min。
8.权利要求1-7所述的一种播娘蒿籽油的制备方法所制备的播娘蒿籽油在制备降血糖药品、食品或保健品中的应用。
9.权利要求1-7所述的一种播娘蒿籽油的制备方法所制备的播娘蒿籽油在制备降血胆固醇药品、食品或保健品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210803200.5A CN115261114A (zh) | 2022-07-07 | 2022-07-07 | 一种具有降血糖和降血胆固醇功效的播娘蒿籽油 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210803200.5A CN115261114A (zh) | 2022-07-07 | 2022-07-07 | 一种具有降血糖和降血胆固醇功效的播娘蒿籽油 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115261114A true CN115261114A (zh) | 2022-11-01 |
Family
ID=83765683
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210803200.5A Pending CN115261114A (zh) | 2022-07-07 | 2022-07-07 | 一种具有降血糖和降血胆固醇功效的播娘蒿籽油 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115261114A (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1292411A (zh) * | 1999-06-25 | 2001-04-25 | 四川大学 | 从播娘蒿种子中分离特种油脂的方法 |
CN1313040A (zh) * | 2001-03-23 | 2001-09-19 | 樊劲 | 降脂降压保健食品 |
CN1326764A (zh) * | 2001-06-06 | 2001-12-19 | 李宜蓬 | 降血脂的药物 |
CA2585798A1 (en) * | 2004-12-17 | 2006-06-17 | Metanomics Gmbh | Process for the control of production of fine chemicals |
CN1995304A (zh) * | 2006-10-17 | 2007-07-11 | 颜怀伟 | 药食兼用植物播娘蒿油的制造方法 |
CN102726400A (zh) * | 2012-07-18 | 2012-10-17 | 安徽丰乐农化有限责任公司 | 一种小麦苗后复配除草剂 |
CN105213737A (zh) * | 2015-11-10 | 2016-01-06 | 夏放军 | 一种减肥中药及其制备方法 |
CN111296630A (zh) * | 2020-03-03 | 2020-06-19 | 佛山科学技术学院 | 一种草鱼饲料及其生产方法 |
CN113082190A (zh) * | 2021-05-08 | 2021-07-09 | 江西师范大学 | 强心合剂在制备通过dcm心肌细胞自噬机制而阻断dcm的药物中的用途 |
-
2022
- 2022-07-07 CN CN202210803200.5A patent/CN115261114A/zh active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1292411A (zh) * | 1999-06-25 | 2001-04-25 | 四川大学 | 从播娘蒿种子中分离特种油脂的方法 |
CN1313040A (zh) * | 2001-03-23 | 2001-09-19 | 樊劲 | 降脂降压保健食品 |
CN1326764A (zh) * | 2001-06-06 | 2001-12-19 | 李宜蓬 | 降血脂的药物 |
CA2585798A1 (en) * | 2004-12-17 | 2006-06-17 | Metanomics Gmbh | Process for the control of production of fine chemicals |
CN1995304A (zh) * | 2006-10-17 | 2007-07-11 | 颜怀伟 | 药食兼用植物播娘蒿油的制造方法 |
CN102726400A (zh) * | 2012-07-18 | 2012-10-17 | 安徽丰乐农化有限责任公司 | 一种小麦苗后复配除草剂 |
CN105213737A (zh) * | 2015-11-10 | 2016-01-06 | 夏放军 | 一种减肥中药及其制备方法 |
CN111296630A (zh) * | 2020-03-03 | 2020-06-19 | 佛山科学技术学院 | 一种草鱼饲料及其生产方法 |
CN113082190A (zh) * | 2021-05-08 | 2021-07-09 | 江西师范大学 | 强心合剂在制备通过dcm心肌细胞自噬机制而阻断dcm的药物中的用途 |
Non-Patent Citations (2)
Title |
---|
刘忠良: "南葶苈子提取物调血脂作用的实验研究", 《药学实践杂志》, vol. 18, no. 1, pages 4 * |
李超: "南葶苈子脂肪油成分的提取、分离和成分鉴定研究", 《中国优秀博硕士学位论文全文数据库(硕士)医药卫生科技辑》, pages 2 - 1 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2345416B1 (en) | Pharmaceutical composition for purifing vein and preparation method thereof | |
CN102318829A (zh) | 一种具有降血压功能的复方山茶油保健品及其制备方法 | |
CN107349292A (zh) | 一种抑脂化脂降糖解油的减肥茶及其制备方法 | |
CN115261114A (zh) | 一种具有降血糖和降血胆固醇功效的播娘蒿籽油 | |
CN117919301A (zh) | 一种含有三七和葛根的降血脂的中药组合物及其制备方法 | |
CN112655967A (zh) | 一种以马齿苋提取物为壁材的大籽蒿精油微胶囊及其制备方法 | |
CN101096629B (zh) | 一种枇杷花醋及其制备方法 | |
CN110882359A (zh) | 一种纳曲制剂及其制备方法 | |
CN103689590B (zh) | 一种辅助降血脂的保健食品及其制备方法 | |
CN112057535B (zh) | 一种预防或/和治疗血脂异常的中药组合物的制备方法 | |
CN109699887B (zh) | 一种牡丹籽油降血脂软胶囊及其制备方法 | |
CN106754057A (zh) | 一种保健红曲糯米酒及其制备方法 | |
CN105941663A (zh) | 一种具有降血脂功能的油脂组合物 | |
CN101612296B (zh) | 治疗心脑系统疾病、中风后遗症的药物在制备治疗脂肪肝的药物中的用途 | |
CN1225270C (zh) | 一种治疗动脉粥样硬化的药物及其制备方法 | |
CN110959721A (zh) | 一种食凉茶固体饮料 | |
CN117860801B (zh) | 一种具有综合调节血脂作用的鱼油中药复合物及其制备方法和应用 | |
CN115154508B (zh) | 一种中药复方纳米粒的制备方法及应用 | |
CN118845914B (zh) | 含沉香叶的降血脂组合物及其制备方法和用途 | |
CN109758492A (zh) | 一种菊花总黄酮及其制备方法和应用 | |
CN115089635A (zh) | 一种富含植物甾醇且具有降血糖和降血胆固醇功效的陈皮油 | |
CN112057536B (zh) | 一种预防或/和治疗血脂异常的中药组合物及其应用 | |
CN106581142A (zh) | 一种复方调血脂的中药组合物及其用途 | |
CN108260818A (zh) | 一种具有降血脂、降血糖、降血压、提高免疫力功能的保健食品及其制备方法 | |
CN112352953A (zh) | 一种预防心脑血管病的组合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20221101 |